Research and Markets has announced the addition of The Pharmaceutical Market: Cuba - 2007 Update from Espicom Business Intelligence to their offering.
These in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
6.Organisation & Administration
10.Pharmaceutical Market Environment
Cuba is one of the world’s last unreconstructed communist countries. Ruled since the 1950s by Dr Fidel Castro, Cuba has attempted none of the economic reforms implemented in Eastern Europe or even China. Despite this, the country has a reputation for the quality of its health services and health indicators, and has an impressive pharmaceutical/biotechnology research sector. This reputation is deserved in part, but conceals an ageing healthcare system in dire need of restructuring and modernising, none of which can be achieved without greatly increased funding.
During the Cold War, Cuba was a major Soviet ally, and the market remained largely closed to the West. During the 1990s, however, many countries in the West established links with Cuba. The USA, virtually alone, maintains its embargo against Cuba. This is starting to hurt US healthcare firms, as companies based in Asia, Canada and Western Europe have the high-tech market to themselves. The international healthcare industry is taking an increasing interest in Cuba, which in turn has made efforts to integrate into the global marketplace in an attempt to attract new funding for its healthcare system.
Since its realignment under the consortium QUIMEFA in 2001, domestic pharmaceutical production has kept growing, with increasing biotechnology export opportunities not only in developing countries but also in Europe and other developed countries. Cuba maintains a list of essential medicines (CBM), with 827 in 2005, of which 521 are domestically produced. There is no commercial advertising in Cuba, instead advertising has an educational purpose. Cuba affords some level of pharmaceutical patent protection, although less than international norms. Since 2001, FARMACUBA has acted as importer, exporter and distributor for QUIMEFA.
CIGB (Heber Biotec)
Roberto Escudero Diaz
8 de Marzo
Genesis Medical Technologies